Neuropathic Pain Medical Cannabis UK

Neuropathic Pain and Medical Cannabis: UK Overview

• Neuropathic pain is one of the most common and well-evidenced indications for medical cannabis prescribing in the UK.
• Conditions causing neuropathic pain include diabetic neuropathy, post-herpetic neuralgia, spinal cord injury, and chemotherapy-induced peripheral neuropathy.
• Both THC and CBD interact with pain receptors relevant to neuropathic pathways, including TRPV1 and CB1/CB2 receptors.
• Patients typically need to have failed gabapentin, pregabalin, amitriptyline, and/or duloxetine before being prescribed cannabis.

Neuropathic pain is notoriously resistant to standard analgesics and represents one of the most significant areas of unmet need in UK pain medicine. Medical cannabis is increasingly recognised as a clinically valuable option for patients with documented treatment-resistant neuropathic pain.

Evidence for Cannabis in Neuropathic Pain

• The NICE chronic pain guideline (NG193, 2021) acknowledged cannabis-based medicines as an option for neuropathic pain, though with caveats.
• Multiple systematic reviews confirm moderate evidence for THC-containing products reducing neuropathic pain intensity.
• Drug Science TWENTY21 included a large neuropathic pain cohort, showing statistically significant improvements in pain scores.
• Sativex has demonstrated efficacy in central neuropathic pain associated with multiple sclerosis in randomised trials.

The evidence base for cannabis in neuropathic pain is the strongest of any pain indication, with multiple RCTs supporting efficacy. UK prescribers are therefore relatively confident in this indication, and access through specialist clinics is generally straightforward for eligible patients.

Accessing Cannabis for Neuropathic Pain in the UK

• Self-refer to a UK specialist cannabis clinic; no GP referral is required at most private providers.
• Document your neuropathic pain diagnosis and provide evidence of at least two failed standard treatments.
• Attend a virtual or in-person consultation; the prescriber will select a product based on pain type and severity.
• Begin with a low dose and titrate upward; most patients reach a therapeutic dose within four to eight weeks.

Neuropathic pain patients often achieve a meaningful response to medical cannabis within the first month of treatment. Regular follow-up is essential to fine-tune the dose and product selection as tolerance and response evolve.

Costs for UK Neuropathic Pain Patients

• Initial specialist consultation: £150–£280 at major UK private clinics.
• Monthly medication: £100–£250 depending on product type (oil, dried flower) and dosage.
• Some UK NHS trusts are exploring pathways for NHS-funded neuropathic pain cannabis prescriptions.
• Follow-up appointments every one to three months are standard and essential for prescription optimisation.

Neuropathic pain patients who have failed multiple conventional medications often find the monthly cost of medical cannabis justified by the improvement in pain control and quality of life. A frank discussion about expected costs should form part of the initial consultation.